Undisclosed payments by pharmaceutical and medical device manufacturers to authors of endoscopy guidelines in the United States.
Payments from pharmaceutical and medical device manufacturers to authors of clinical practice guidelines (CPG) may influence practice recommendations. It is therefore important to evaluate the completeness of financial conflict of interest (FCOI) declarations among CPG authors. We performed a cross-sectional analysis of industry payments to authors of endoscopy guidelines published by 5 GI societies between 2014 and 2017. For each author, we identified payments using the disclosure section of CPGs and the Centre for Medicare & Medicaid Services Open Payments (CMS-OP) database. We calculated the prevalence, monetary value, and type of declared and undeclared payments among authors. Payments were assessed for the calendar year of and before publication. Thirty-seven CPGs were included in the analysis comprising 569 author entries (91 unique individuals; 66.43% male, 92.6% physicians, 66.4% academically affiliated). Four hundred fifty-one (79%) episodes involved FCOI, 451 (79%) had undisclosed FCOI in CMS-OP, and 445 (77%) had FCOI relevant to a CPG recommendation. The median (IQR) undisclosed payment value was $4,807.26 ($334.84-$20,579.75). Male (OR, 2.23; 95% CI, 1.47-3.39) and academically affiliated (OR=, 8.87; 95% CI, 5.57-14.13) authors were significantly more likely to have undeclared payments (P<.001). No CPGs met all National Academy of Medicine criteria. Recognizing concerns about the accuracy of CMS-OP, there are substantial discrepancies between industry reported payments and author self-disclosure. Additionally, there is a high prevalence of undisclosed payments by pharmaceutical and medical device manufacturers to these authors. Given the potential impact of these discrepancies and undisclosed payments on CPGs, more accurate reporting and alternative strategies for managing FCOI are needed.